The Prognosis For Palvella Therapeutics
2026-06-03 14:09:30 ET
Shares of rare skin disease and vascular malformations concern Palvella Therapeutics, Inc. ( PVLA ) have increased over seven-fold since going public in December 2024 on the back of strong results for its lead asset. QTORIN rapamycin produced approvable data in its pivotal trial treating microcystic lymphatic malformations, setting up a 2H26 NDA filing with pipeline-in-product and blockbuster potential. With one Phase 3 and two Phase 2 trial initiations anticipated over the next eight months and no approved therapies across its four targeted indications, the surge in Palvella merited a deeper dive. An analysis follows below....
Read the full article on Seeking Alpha
For further details see:
The Prognosis For Palvella Therapeutics
NASDAQ: PVLA
PVLA Trading
-3.43% G/L:
$110.05 Last:
116,470 Volume:
$112 Open:
